XARELTA 20 Tablet

About XARELTA 20 Tablet

XARELTA 20 comes as a tablet with 20 mg of Rivaroxaban, from Opsonin Pharma Limited. XARELTA 20 is used in adults to lower the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, and in the treatment of deep vein thrombosis and pulmonary embolism.

There are 19 brands of Rivaroxaban listed in Bangladesh. The lowest listed price is Rivadel 2.5 Tablet at ৳ 5 per unit.

What is XARELTA 20 Tablet?

Made by Opsonin Pharma Limited, XARELTA 20 is a tablet whose active ingredient is Rivaroxaban. Rivaroxaban works by blocking factor Xa, a substance in the blood clotting process, which reduces the formation of thrombin and helps make clots less likely. It is important to take it exactly as instructed and not to stop it without medical advice, because stopping suddenly can raise the risk of clots. The dose and course are set by the doctor.

Uses of XARELTA 20

XARELTA 20 is used in adults to lower the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, and in the treatment of deep vein thrombosis and pulmonary embolism. XARELTA 20 is used in adults after an acute coronary syndrome where cardiac biomarkers are raised, to help prevent atherothrombotic events. XARELTA 20 is used in adults after acute coronary syndrome when cardiac biomarkers such as troponin or CK-MB are elevated. Whether it suits a particular person depends on their condition and medical history, so the doctor decides if it is appropriate.

How to use XARELTA 20

Take XARELTA 20 exactly as your doctor tells you. Swallow the tablet with water. XARELTA 20 is taken by mouth. Do not stop, skip or change the medicine on your own, since stopping suddenly can raise the risk of clotting problems. Do not change the amount or stop taking it on your own, because stopping suddenly can raise the risk of clots.

Side effects of XARELTA 20

Call your doctor promptly if you notice unusual or prolonged bleeding, or any sign of neurological problems such as weakness or numbness. In people with nonvalvular atrial fibrillation, stopping the medicine raises the risk of stroke. Bleeding may appear as bruising, nosebleeds, gum bleeding or blood in the urine or stool, and in some cases it can be serious. Ask your doctor or pharmacist about any other effects you notice while taking XARELTA 20. Tell your doctor if any side effect bothers you or does not go away.

Safety and precautions

Pregnant or breastfeeding women, and anyone with kidney or liver problems, should speak to a doctor before use. Before taking XARELTA 20, tell your doctor if you have a bleeding disorder, uncontrolled high blood pressure, stomach or bowel disease, eye blood vessel problems, or a history of lung bleeding. It is not recommended during pregnancy or breastfeeding without specialist advice, as safety has not been established. Ask your doctor first if any of these apply to you.

Frequently asked questions

What does XARELTA 20 treat?

XARELTA 20 is used in adults to lower the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, and in the treatment of deep vein thrombosis and pulmonary embolism. XARELTA 20 is used in adults after an acute coronary syndrome where cardiac biomarkers are raised, to help prevent atherothrombotic events.

How do I use XARELTA 20 correctly?

Take XARELTA 20 exactly as your doctor tells you. Swallow the tablet with water.

What are the side effects of XARELTA 20?

Call your doctor promptly if you notice unusual or prolonged bleeding, or any sign of neurological problems such as weakness or numbness. In people with nonvalvular atrial fibrillation, stopping the medicine raises the risk of stroke.

Is XARELTA 20 safe for everyone?

Pregnant or breastfeeding women, and anyone with kidney or liver problems, should speak to a doctor before use. Before taking XARELTA 20, tell your doctor if you have a bleeding disorder, uncontrolled high blood pressure, stomach or bowel disease, eye blood vessel problems, or a history of lung bleeding.

Indications

Rivaroxaban 2.5 mg:
  • For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg ... Read moreRivaroxaban 2.5 mg:
  • For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg:
  • To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  • Deep vein thrombosis (DVT) & pulmonary embolism (PE) and reduction in the risk of recurrence of DVT and of PE
  • For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

Pharmacology

Rivaroxaban is a highly selective direct factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibits thrombin formation. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Dosage & Administration

Rivaroxaban 2.5 mg:
  • The recommended dose: 2.5 mg twice daily. Patients should also take a daily dose of 75-100 mg Aspirin or a daily dose of 75-100 mg Aspirin in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.
Rivaroxaban 10-20 mg:
  • Nonvalvular Atrial Fibrillation: For patients with Creatinin Clearance >50 mL/min: 20 mg orally, once daily with the evening meal. For patients with Creatinin Clearance 15-50 ml/min: 15 mg orally, once daily with the evening meal.
  • Treatment of DVT & PE: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment.
  • Prevention in the risk of recurrence of DVT and of PE: 20 mg once daily with food.
  • Prophylaxis of DVT following Hip replacement surgery: 10 mg once daily for 35 days.
  • Prophylaxis of DVT following knee replacement surgery: 10 mg once daily for 12 days.
May be taken with or without food.

Interaction

Concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin, fluconazole, diltiazem, verapamil, dronedarone) increases in Rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation), that’s why should be avoided. Co-administration of Rivaroxaban with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin, carbamazepine) decreases the efficacy of Rivaroxaban and also should be avoided. The concomitant use of other drugs like anti-platelet agents, heparin, fibrinolytic therapy, NSAIDs may cause an increased risk of bleeding.

Contraindications

It is contraindicated in patients with known hypersensitivity of Rivaroxaban or any of the excipients of the product. It is also contraindicated in patients with active pathological bleeding.

Side Effects

The most common side effects of Rivaroxaban have increased chance of bleeding, spinal or epidural hematoma and increased risk of stroke after discontinuation in nonvalvular atrial fibrillation.

Pregnancy & Lactation

Rivaroxaban is a pregnancy category C drug. There are no adequate or well-controlled studies of Rivaroxaban in pregnant women, and dosing for pregnant women has not been established. It is not known if Rivaroxaban is excreted in human milk. The safety and efficacy of Rivaroxaban has not been established in breastfeeding women.

Precautions & Warnings

Early discontinuation of Rivaroxaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. Rivaroxaban increases the risk of bleeding that can be fatal in presence of following risk factors- bleeding disorders, uncontrolled severe arterial hypertension, gastrointestinal disease (e.g., inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease), vascular retinopathy, bronchiectasis, history of pulmonary bleeding. Signs or symptoms of neurological impairment should be monitored in case of neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture as epidural or spinal hematoma can occur. Rivaroxaban is not recommended in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

Overdose Effects

Overdose of Rivaroxaban may lead to hemorrhage. Rivaroxaban systemic exposure is not further increased at single doses >50 mg due to limited absorption. A specific antidote for Rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of Rivaroxaban overdose may be considered. Partial reversal of laboratory anticoagulation parameters may be achieved with use of plasma products.

Storage Conditions

Store in a cool (below 30°C) & dry place protected from light. Keep away from the reach of children.

Alternative brands of Rivaroxaban

Other brands with the same generic name, cheapest first.

See all 19 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.